Cassava Sciences (SAVA) said Tuesday that topline results from its phase 3 REFOCUS-ALZ study of simufilam showed no treatment benefit for patients with mild-to-moderate Alzheimer's disease.
The biotech company said the results did not meet the co-primary, secondary, and exploratory biomarker endpoints.
The co-primary endpoints were the change in cognition and function from baseline to the end of the double-blind treatment period at week 76 compared to placebo.
Shares of Cassava Sciences were down 18% in recent premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。